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Edited by Hans EklundAbstract Direct comparisons of human (h) and murine (m) neu-
trophil elastase (NE) and proteinase 3 (PR3) are important for
the understanding and interpretation of inﬂammatory and
PR3-related autoimmune processes investigated in wild-type-,
mNE- and mPR3/mNE knockout mice. To this end, we puriﬁed
recombinant mPR3 and mNE expressed in HMC1 and 293 cells
and compared their biophysical properties, proteolytic activities
and susceptibility to inhibitors with those of their human homo-
logues, hPR3 and hNE. Signiﬁcant species diﬀerences in phys-
ico-chemical properties, substrate speciﬁcities and enzyme
kinetics towards synthetic peptide substrates, oxidized insulin
B chain, and ﬁbrinogen were detected. MeOSuc-AAPV-pNA
and Suc-AAPV-pNA were hydrolyzed more eﬃciently by
mPR3 than hPR3, but enzymatic activities of mNE and hNE
were very similar. Fibrinogen was cleaved much more eﬃciently
by mPR3 than by hPR3. All four proteases were inhibited by a1-
antitrypsin and elaﬁn. Eglin C inihibited mNE, hNE, mPR3, but
not hPR3. SLPI inhibited both NEs, but neither PR3. The cus-
tom-designed hNE inhibitor, Val15-aprotinin, is a poor inhibitor
for mNE. In conclusion, appropriate interpretation of experi-
ments in murine models requires individual species-speciﬁc
assessment of neutrophil protease function and inhibition.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Human neutrophil elastase (hNE, EC 3.4.21.37) and pro-
teinase 3 (hPR3, EC 3.4.21.76) are neutral serine proteases
stored in granules of neutrophils and monocytes. They share
55% amino acid homology and many structural and functional
characteristics [1–3].
HNE has been studied for decades because of its pathophys-
iologic role in diseases ranging from acute lung injury andAbbreviations: ANCA, anti-neutrophil cytoplasmic antibodies; HMC-
1, human mast cell line 1; NE, neutrophil elastase; PR3, proteinase 3;
h, human; m, murine; MeO, methoxy; Suc, succinyl; pNa, paranitro-
anilide; SLPI, secretory leukoprotease inhibitor
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in hPR3 has arisen because it is the target antigen for speciﬁc,
seemingly pathogenic autoantibodies anti-neutrophil cytoplas-
mic antibodies (ANCA) in Wegeners granulomatosis [6–8],
and because an HLA-A2.1-restricted hPR3-derived nonamer
has been identiﬁed as a leukemia-associated antigen with ther-
apeutic potential [9].
Despite similarities in substrate speciﬁcity and inhibitor
spectrum, signiﬁcant functional diﬀerences between the two
proteases become recognized [10]. Insights about the biological
functions of neutrophil serine proteases and their contribu-
tions to disease in vivo are increasingly extrapolated from tar-
geted gene knock-out mice [11–15]. However, the functional
characteristics of the murine neutrophil serine proteases have
not yet been studied. Several lines of evidence suggest that bio-
logically relevant functional diﬀerences between the proteases
from diﬀerent species should be anticipated. For instance, hu-
man and rodent a-chymases have 72% sequence homology.
Yet, the rodent isozymes do not behave chymotrypsin-like as
human a-chymases do, but are elastase-like proteases [16]. Dif-
ferent substrate speciﬁcities and possible biological functions
are also suggested by the diﬀerent protease inhibitor-repertoire
of mice [17–19]. Consequently, more detailed knowledge about
the functional similarities and dissimilarities of murine neutro-
phil elastase (mNE) and proteinase 3 (mPR3) compared to
their human homologues is necessary for the appropriate inter-
pretation of mouse model experiments.
This is the ﬁrst study to evaluate substrate speciﬁcities and
inhibitor proﬁles of mPR3 and mNE. Until now, such studies
have been limited by the availability of puriﬁed mPR3 and
mNE. Our ﬁndings indicate that physico-chemical properties
and functional characteristics of hPR3andmPR3diﬀer substan-
tially. Despite more signiﬁcant functional similarities between
hNE and mNE, custom-designed inhibitors for hNE may be
poor inhibitors for mNE. Therefore, individual functions and
inhibitors need to be evaluated in a species-speciﬁc manner.2. Materials and methods
2.1. Materials
All reagents were from Sigma (St. Louis, MO), unless speciﬁed
otherwise. Elaﬁn was from Peptides International, Inc. (Louisville,
KY), Secretory Leukocyte Protease Inhibitor (SLPI) from R&D
Systems (Minneapolis, MN), puriﬁed human neutrophil PR3
(PMN-hPR3) and elastase (PMN-hNE) from Athens Research andblished by Elsevier B.V. All rights reserved.
5306 O. Wiesner et al. / FEBS Letters 579 (2005) 5305–5312Technology (Athens, GA). The inhibitor Val15-aprotinin was a kind
gift from Prof. Gordon Lowe, Dyson Perris Laboratory, Oxford,
UK [20]. The human mast cell line, HMC-1, was a kind gift from
Dr. Joseph Butterﬁeld, Mayo Clinic, Rochester, MN; the human kid-
ney epithelial cell line, 293, were purchased from the American Type
Tissue Culture.
2.2. Expression of recombinant serine proteases
The cDNA constructs used are shown in Fig. 1A. Generation of
wild-type hPR3 and mPR3 cDNA, corresponding expression plas-
mids, and transfection into HMC-1 cells have been described [21,22].
The mPR3 cDNA was ampliﬁed from total bone marrow cDNA
using the primers DJ398 (5 0-CCAGGTACCTGTCCATGGCTG-
GAAGCT-30) and DJ427 (5 0-AAGGGTACCTCAGGGCCCTGC-
3 0). The ampliﬁed product subcloned into the KpnI restriction site of
a pcDNA3.1/Zeo vector (Invitrogen). The resulting plasmid was line-
arized with ApaI at the 3 0 end of the mPR3 insert, and the coding se-
quence for a cmyc-poly-His-tag was added. This sequence was derived
from a pPICZ vector by digestion with ApaI and BamHI. Before liga-
tion into the ApaI site, the BamHI was ﬁlled in to generate two blunt
ends and to reconstitute the BamHI site of the pcDNA3.1 expression
plasmid.
The cDNA construct hPR3-cmyc coding for full-length hPR3 with a
carboxy-terminal cmyc-poly-His-tag was transfected into 293 cells [23].
The mNE cDNA was similarly ampliﬁed from total bone marrow
cDNA using the primers DJ566 (5 0-GGGGATCCGCGAGAACA-
CAGCC-30) and DJ 567 (5 0-GGGGTGGGAGTGCAGACAGGT-
3 0). The PCR product was digested with BamHI.
The cDNA construct mNE-cmyc codes for full-length mNE carrying
the carboxy-terminal cmyc-poly-His-tag. It was generated by adding
HindIII and XbaI restriction sites to the cDNA coding for full-length
mNE using primers OW1 (5 0-AAGCTTGGTACCGAGCTCG-
GATCC-3 0) and OW2 (5 0-TCTAGAGTTGG-TCCTGCCCTC-30).
The resulting insert was cloned into the HindIII/Xba I-restricted
expression vector pcDNA4/Myc-HisA (Invitrogen). The nucleotide se-Fig. 1. Expression of recombinant human and murine neutropil serine prote
peptide, amino-terminal activation-dipeptide, mature enzyme, and carboxy-te
cDNA constructs coding for wild-type hPR3 and mPR3 were transfected into H
from HMC-1/hPR3 and HMC-1/mPR3 cells. The cDNA constructs hPR3-cm
carrying a carboxy-terminal cmyc-poly-His-tag. They were transfected into 29
were puriﬁed from the culture supernatant and activated by amino-terminal cquence for mNE was identical to the published sequence, XM_109573
(GenBank). The plasmid was transfected into 293 cells, and expressing
293/mNE-cmyc cell clones were selected using Zeocin (Gibco, Grand
Island, NY, USA) [24].
2.3. Puriﬁcation of recombinant hPR3 and mPR3 from HMC-1 cells
Recombinant hPR3 was expressed in HMC-1 cells [21]. HMC-1/
hPR3 cells were lysed by repeated freezing and thawing followed by
incubation in 0.02 M Tris–HCl, 0.15 M NaCl, 1% Triton X-100, pH
7.4. After centrifugation, the supernatant was diluted 1:3 with water,
extracted with Accell QMA (water, 0.3 mg/ml) and centrifuged. The
supernatant was adjusted to pH 5.5 and applied to a Mono S column
(Pharmacia) equilibrated in 0.05 M NaOAc, pH 5.5. Proteins were
eluted with a linear gradient from 0 to 3 M NaCl and then with
0.05 M NaOAc, 1 M NaCl, 0.1% Triton X-100, pH 5.5 (Fig. 2A).
Immunoreactivity [25] and hydrolytic activity were monitored
throughout the various steps of the puriﬁcation. A signiﬁcant portion
of bound hPR3 was eluted around 1.5 M NaCl (hPR3-salt). The peak
of immunoreactivity eluted ﬁrst and displayed little hydrolytic activity
suggesting that these fractions contain a large proportion of incom-
pletely processed pro-hPR3. A signiﬁcant proportion of hPR3 could
only be eluted with 0.1% Triton X-100 (hPR3-Tx100). The SDS-elec-
trophoretic migration patterns of hPR3-salt and hPR3-Tx100 were
similar (Fig. 2A). However, the lowest molecular mass band (most
highly processed) was more prominent in the hPR3-Tx100 pool. Both,
puriﬁed hPR3-salt and hPR3-Tx-100 were dialyzed against 0.05 M
MES, 0.7 M NaCl, pH 4.5 (same as the PMN-hPR3 and PMN-hNE
buﬀer) and stored at 20 C in plastic tubes until use.
Recombinant mPR3 was expressed in HMC-1 cells [22]. After gentle
washing in PBS, HMC-1/mPR3 cells were suspended in 10 ml of PBS,
ﬁxed with 40 ml of cold 95% ethanol and stored at 4 C overnight.
After centrifugation the pellet was brought up in PBS, centrifuged,
and the supernatant was subjected to sequential 40% and 55% etha-
nol-precipitation. The supernatant was then subjected to 80% etha-
nol-precipitation. The resulting precipitate was dissolved in 0.01 Mases. (A) Schematic diagram of the cDNA constructs used. The signal
rminal propeptide sequences are indicated. (B) Plasmids containing the
MC-1 cells. The expressed recombinant hPR3 andmPR3 were puriﬁed
yc, mPR3-cmyc, and mNE-cmyc code for the full length pro-enzymes
3 cells. Using the carboxy-terminal cmyc-poly-His-tag, the pro-enzymes
leavage of the activation-dipeptide with bovine cathepsin C.
Fig. 2. Puriﬁcation of human and murine recombinant PR3 from
HMC-1 cells. (A) Recombinant hPR3. Proteins from HMC-1/hPR3
cell lysate and not bound to an anion exchanger were applied to a
Mono S column and eluted with (1) a linear gradient from 0 to 3 M
NaCl, and (2) 0.05 M NaOAc, 1 M NaCl, 0.1% TritonX-100, pH 5.5
(arrow). The hPR3 concentrations (dashed line) were determined by
hydrolysis of MeOSuc-AAPV-pNA and based on active site titration
data. Immunologically reactive hPR3 was quantiﬁed by capture
ELISA (solid line) [25]. The inset shows SDS–PAGE (12% gel) of
TCA-precipitated samples taken at diﬀerent stages of puriﬁcation.
Lanes 1 and 2 represent 20 lg total protein of the cell lysate and QMA
supernatant, respectively. Lanes 3 and 4 represent 5 lg of total protein
from the corresponding indicated elution peaks. (B) Recominant
mPR3. The phenyl-superose column was equilibrated in 0.3 M NaOAc
pH 5.5, loaded with prepared sample and eluted with (1) a linear
gradient to 0.05 M NaOAc, pH 5.5 and (2) a linear gradient to 25% 2-
propanol. The mPR3 concentrations (solid line) were determined by
hydrolysis of MeOSuc-AAPV-pNA and based on active site titration
data. Insrt: Cell lysate containing 1 lg of active mPR3 (lane 1), Mono
Q ﬂow through containing 2 lg of active mPR3 (lane 2), and puriﬁed
material from the Phenyl-Superose elution peak (3) containing 2 lg of
active mPR3 (lane 3), were TCA-precipitated and separated by SDS–
PAGE (12% gel).
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(Pharmacia) equilibrated with the same buﬀer. The ﬂow-through was
again subjected to 80% ethanol-precipitation. The precipitate was dis-
solved in 0.02 M Tris–HCl, 0.15 M NaCl, pH 7.4, to which an equal
volume of 0.3 M NaOAc, pH 5.5 was added. After centrifugation
the supernatant was applied to a phenyl-superose column equilibrated
with 0.3 M NaOAc, pH 5.5 and subjected to a linear gradient to
0.05 M NaOAc, pH 5.5. The mPR3 was eluted with a linear gradient
to 50% 2-propanol in 0.05 M NaOAc, pH 5.5 (1:1, v/v) (Fig. 2B),
and stored in the elution buﬀer at 4 C in glass tubes until use. Ami-
no-terminal sequencing of the predominant 30 kDa band (SDS–PAGE
and PVDF blot) yielded the sequence Ile-Val-Gly-Gly-Glu-__-__-Pro-
__-, consistent with the published sequence of mPR3 [22].2.4. Puriﬁcation of recombinant pro-enzymes expressed in 293 cells
Variants of hPR3, mPR3 and mNE carrying a carboxy-terminal
cmyc-poly-His-tag were expressed in 293 cells. These are referred to
as hPR3-cmyc, mPR3-cmyc, and mNE-cmyc, respectively. For puriﬁ-
cation of the pro-enzymes from stably transfected 293 cell clones, cul-
ture supernatants were dialyzed against 20 mM phosphate, 0.5
M NaCl, 10 mM imidazole, pH 7.4 (binding buﬀer), and applied to a
HiTrap chelating HP column (Amersham Pharmacia Biotech Inc,
NJ, USA). The columns were washed twice with binding buﬀer and
once with 20 mM phosphate, 0.5 M NaCl, 50 mM imidazole, pH 7.4.
Proteins were eluted in one step with 20 mM phosphate, 0.5 M NaCl,
500 mM imidazole (100 mM for mPR3-cmyc), pH 7.4.
2.5. Activation of puriﬁed pro-enzymes with cathepsin C
Because recombinant neutrophil serine proteases secreted by 293
cells are not amino-terminally processed, puriﬁed hPR3-cmyc,
mPR3-cmyc and mNE-cmyc were activated in vitro by amino-terminal
cleavage of the activation-dipeptide. For mPR3-cmyc and mNE-cmyc,
50 lg/ml of proenzyme were incubated with 1.5 U/ml of cathepsin C in
33 mMMES, 467 mM NaCl, 30 lMDTT, pH 4.5 for 20 h at RT. Un-
der these conditions hPR3-cmyc does not activate very well. Hence,
50 lg/ml of pro-enzyme were incubated with 1.5 U/ml of cathepsin C
in 33 mM NaOAc, 0.66 mM NaCl, 28 mM DTT, pH 5.5 for 8 h at
RT. Cleavage of the activation dipeptide by cathepsin C was moni-
tored by hydrolysis of MeOSuc-AAPV-pNA.
2.6. Determination of enzyme concentrations by active site titration
Each enzyme was labeled with >50x molar excess of 3H-diisopropyl-
ﬂuorophosphate (3H-DFP, Perkin/Elmer Life Sciences, Boston, MA).
Enzymes were TCA-precipitated, radioactivity counted, and counts
plotted against a standard curve of known trypsin concentrations,
which were determined with cleavage of p-nitrophenyl p 0-guanidino-
benzoate [26]. Based on this active site titration, enzymes were diluted
to the desired concentrations in 0.01% aqueous Triton X-100 and
added to the assay buﬀers.
2.7. Enzyme activity assays
To characterize enzymatic activities of the diﬀerent neutrophil serine
proteases from both species, kinetic assays with the substrates MeO-
Suc-AAPV-pNa, Suc-AAPV-pNa, MeOSuc-AIPM-pNa, Suc-AAPL-
pNa, Suc-AAA-pNa, and Suc-AAPF-pNa (Bachem, King of Prussia,
PA) were performed in 100 ll of 90 mM Tris, 52 mM NaCl buﬀer con-
taining 0.5% Triton X-100 (w/v) and 10% dimethylformamide (v/v),
pH 8.0. Except where indicated, values are expressed as the
means(±standard error) of three separate determinations. The values
of each determination represent the average of those estimated from lin-
ear regression analysis of Lineweaver–Burk, Hanes–Woolf and Eadie–
Hofstee plots. Vmax values were based on a molar absorbance of 2448
(A405 nm–A490 nm) for 100 ll of 4-nitroaniline in a microtiter plate well.
Bovine oxidized insulin B chain (30 lM, HPLC-puriﬁed) was
digested with 3–25 nM enzyme in 0.08 M Tris, 0.1 M NaCl, pH 8.
Reactions were terminated with glacial acetic acid. Digests were sub-
jected to HPLC on a Vydac Protein and Peptide C18 column. Solvent
A was 0.07% aqueous triﬂuoroacetic acid (TFA) and solvent B was
0.05% TFA in acetonitrile. Peptides were separated at a ﬂow rate of
1 ml/min using a linear gradient from 10% B to 40 % B over 30 min
(detection at 214 nm). Peaks were collected and peptides identiﬁed
by amino acid analysis using acid hydrolysis.
Bovine ﬁbrinogen (32 lM) was digested with 36 nM enzyme in
0.05 M Tris–HCl, 0.15 M NaCl, pH 7.4 (TBS). At various intervals,
the clotting time of the digested ﬁbrinogen was measured in a CoaScre-
ener Hemostasis Analyzer (American Labor Corp., Largo, FL); 50 ll
of digest was added to 200 ll TBS, incubated for 2 min at 37 C,
and ﬁbrin was generated by the addition of 5 ll of bovine thrombin.
Similarly, aliquots of digests were taken at the speciﬁed times for SDS–
PAGE (PhastSysteme, Amersham Biosciences, Piscataway, NJ).
Enzymatic activity was stopped by dilution with reducing sample prep-
aration buﬀer followed by heating for 10 min at 90 C.
2.8. Inhibitor studies
Enzyme and inhibitor were incubated for 1 h at RT in 50 ll of
60 mM Tris, 80 mM NaCl, pH 8.0; residual enzymatic activity was
determined by adding 50 ll of 2 mM MeOSuc-AAPV-pNA, 0.1 M
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Except where indicated, values are the mean (± standard error) of three
determinations. Concentrations of a1-antitrypsin and SLPI were deter-
mined by assay with trypsin, concentration of eglin C by assay with
chymotrypsin, and concentrations of elaﬁn and Val15-aprotinin were
based on suppliers information. Concentrations of enzyme ranging
from 3 to 93 nM were used.3. Results and discussion
3.1. Eﬀect of diﬀerent processing of recombinant proteases on
enzymatic activity
To obtain suﬃcient quantities of puriﬁed murine proteases
for functional studies, two mammalian expression systems
were employed [21,24]. Recombinant hPR3 and mPR3 were
expressed in HMC-1 and 293 cells, and mNE-cmyc in 293 cells.
In HMC-1 cells, a large proportion of the nascent serine pro-
tease is processed intracellularly to the active enzyme, which is
stored in granules [21,22]. In contrast, recombinant neutrophil
proteases expressed in 293 cells are mostly secreted into the cell
supernatant as unprocessed pro-enzymes [24]. This allows
modiﬁcation of the unprocessed carboxy-terminus to facilitate
subsequent puriﬁcation [23], but in vitro cleavage of the amino-
terminal pro-peptide is necessary for activation. The mature
neutrophil serine proteases stored in HMC-1 cell granules
and the pro-enzymes secreted into 293 cell supernatants also
carry diﬀerent Asn-linked glycans [21,24].
To ascertain potential eﬀects of diﬀerences inherent to the
expression systems, we ﬁrst compared enzymatic activities of
puriﬁed recombinant hPR3 and mPR3 expressed in the two
diﬀerent cell types. Digestion of oxidized insulin B chain by
puriﬁed human PMN-PR3, the three diﬀerent recombinant
hPR3 variants, hPR3-salt, hPR3-Tx100 puriﬁed from HMC-Fig. 3. Analysis of cleavage patterns and rates of oxidized insulin B chain. (A
by diﬀerent hPR3 variants. Elution proﬁles are from 8 h digests using 3.5 nM
cleavage rate. The early peak detected in the hPR3-cmyc chromatogram is not
HPLC elution proﬁles of digests of oxidized insulin B chain peptides generat
chain digested with 12 nM PMN-HNE (hNE) for 2 h, or with 25 nM mNE-cm
the early cleavage sites. Cleavage between Val18 and Cys19 produces peaks (
produces peaks (3) Phe1-Val12, and (4) Glu13-Ala30. (C) Summary of HPLC a
mPR3. (D) Summary of HPLC analysis of time-course digests of insulin B-ch
and slow (short) cleavage.1 cells, and hPR3-cmyc puriﬁed from 293 cells, revealed no sig-
niﬁcant qualitative or quantitative diﬀerences in protein-cleav-
age rates or pattern (Fig. 3A). Similarly, the protein-cleavage
patterns and rates of mPR3 expressed in HMC-1 cells did
not diﬀer from those of mPR3-cmyc expressed in 293 cells
(not shown).
The cellular origin of the proteases also did not signiﬁcantly
aﬀect the kinetics of hydrolysis of MeOSuc-AAPV-pNa. Kcat/
Km values (M
1 s1) for the hPR3 variants were: 400 ± 22
(PMN-PR3, n = 5), 499 ± 27 (hPR3-salt, n = 3), 501 ± 24
(hPR3-T · 100, n = 3), and 283 ± 51, (hPR3-cmyc, n = 3).
The Kcat/Km values were 5464 ± 977 (n = 3) for mPR3 from
HMC-1 cells, and 4193 ± 1116 (n = 3) for mPR3-cmyc from
293 cells, respectively. Similarly, the kinetics of hydrolysis of
other substrates listed in Table 1 were equivalent for all four
human PR3 variants (data not shown).
Our comparison of native puriﬁed human PMN-PR3 to
the diﬀerent recombinant hPR3 variants has several implica-
tions. First, it clearly indicates that neither the cleavage of
the carboxy-terminal PR3 pro-peptide (occurring in PMN
and HMC-1 cells), nor the addition of a carboxy-terminal
peptide extension alter enzymatic activity signiﬁcantly. Sec-
ond, diﬀerences in Asn-linked glycans between rPR3 ex-
pressed in HMC-1 and 293 cells compared to PMN-hPR3
[21,24] have no apparent eﬀect on hydrolytic activity. Final-
ly, the diﬀerent puriﬁcation procedures have no eﬀect. The
comparison of recombinant mPR3 expressed in the two dif-
ferent expression systems further corroborates this. Because
of these ﬁndings and because of the simplicity of puriﬁcation
of carboxy-terminally tagged protease variants expressed in 293
cells, we subsequently used recombinant mNE-cmyc for the
direct comparison to native hNE puriﬁed from neutrophils
(Fig. 4).) HPLC elution proﬁles of oxidized insulin B chain peptides generated
enzyme. All hPR3 variants generated the same peptides at the same
a peptide, but an unidentiﬁed component of the cathepsin C digest. (B)
ed by hNE and mNE. These examples show 30 lM oxidized insulin B
yc (mNE) for 30 min. Four peptides are enumerated which deﬁne 2 of
1) Cys19-Ala30 and (2) Phe1-Val18. Cleavage between Val12 and Glu13
nalysis of time-course digests of insulin B-chain, 0.1–20 h, by hPR3 and
ain, 0.1–20 h, by hNE and mNE. Arrows indicate sites of rapid (long)
Table 1
Kinetic parameters for murine and human PR3 and NE enzyme actvity
Substrate Parametera Human PR3b Murine PR3c Murine NEd Human NEe
MeOSuc-AAPV-pNA Kcat 0.59 ± 0.04 6.2 ± 1.0 12.1 ± 2.5 9.2 ± 1.8
Km 1.2 ± 0.02 1.1 ± 0.1 0.52 ± 0.03 0.28 ± 0.02
Kcat/Km 499 ± 27 5464 ± 977 23273 ± 4538 33915 ± 5757
Suc-AAPV-pNA Kcat 0.37 ± 0.08 11.2 ± 0.5 7.1 ± 0.9 5.7 ± 2.0
Km 3.7 ± 0.8 2.5 ± 0.3 0.59 ± 0.03 0.42 ± 0.08
Kcat/Km 98 ± 3 4692 ± 631 12251 ± 2076 13785 ± 3192
MeOSuc-AIPM-pNA Kcat 0.26 ± 0.01 7.2 ± 1.9 1.7 ± 0.06 2.0 ± 0.6
Km 0.61 ± 0.12 1.5 ± 0.3 2.3 ± 0.3 1.2 ± 0.3
Kcat/Km 417 ± 20 4619 ± 175 767 ± 130 1693 ± 135
Suc-AAA-pNA Kcat Very low activity 0.031
f 5.8 ± 1.0 1.2 ± 0.3
Km 0.61 5.9 ± 0.5 2.7 ± 0.2
Kcat/Km 51 966 ± 106 465 ± 103
Suc-AAPL-pNA Kcat Very low activity 0.16 ± 0.14
g 0.67f 0.39f
Km 3.5 ± 2.6 5.5 3.5
Kcat/Km 53 ± 17 122 110
Suc-AAPF-pNA Kcat Not done Not done 0.16
f Very low activity
Km 3.9
Kcat/Km 41
aUnits for Kcat, Km and Kcat/Km are s
1, mM, and M1 s1, respectively.
bData shown for human PR3 were obtained with rhPR3-salt puriﬁed from HMC-1/hPR3 cells.
cData shown for murine PR3 were obtained with mPR3 puriﬁed from HMC-1/mPR3 cells.
dData shown for or murine NE were obtained with mNE-cmyc puriﬁed from 293/mNE-cmyc cells.
eData shown for human NE were obtained with puriﬁed PMN-HNE.
fOne determination.
gTwo determinations.
Fig. 4. Degradation of bovine ﬁbrinogen. Bovine ﬁbrinogen (32 lM) was digested with 36 nM enzyme. (A) 8–25% PhastGele (under reducing
conditions) of bovine ﬁbrinogen digested with PMN-hPR3 (lanes 1–4) and recombinant mPR3 (lanes 5–8). Samples were taken at 0 min (lanes 1 and
5), 10 min (lanes 2 and 6), 45 min (lanes 3 and 7) and 120 min (lanes 4 and 8). PR3-D, PR3 degradation product. (B) Relative disappearance of the
B-beta-chain of bovine ﬁbrinogen upon digestion with PMN-hPR3 (triangles) and recombinant mPR3 (squares) was quantiﬁed by image analysis of
the scanned gel. (C) Thrombin-induced clotting times of undigested bovine ﬁbrinogen (·) and of bovine ﬁbrinogen digested with PMN-hNE (triangles),
recombinant mPR3 (squares) and PMN-hPR3 (diamonds). Shown are representative examples of 3 (A and B) and 5 (C) repeat experiments.
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The puriﬁcation of recombinant hPR3 and mPR3 from
HMC-1 cells required diﬀerent approaches. Puriﬁcation of
hPR3 was dependent on detergent in the cell lysis buﬀer. In
contrast, mPR3 activity was recovered easily out of the
HMC-1 cell supernatants after ethanol ﬁxation of the cells.
Unless the mPR3 expressing HMC-1 cells are exposed to this
ethanol ﬁxation procedure, the hydrolytic activity of mPR3
is lost within minutes. This suggests the presence of either an
inhibitor or an inactivating protease for mPR3 in HMC-1 cells,
which may gain access to the mPR3 as it is released much more
easily from HMC-1 cell granules than its human homologue.
Furthermore, the ﬁnal puriﬁcation steps for hPR3 consisting
of cation-exchange chromatography and elution with a NaCl
gradient (Fig. 2A) resulted only in incomplete elution of
hPR3 between 0.5 and 1.5 M NaCl.
These ﬁndings indicate substantial diﬀerences in physico-
chemical properties between hPR3 and mPR3. It appears that
hPR3 is much more diﬃcult to dislodge from its intracellular
storage compartments in HMC-1 cells than mPR3. One pos-
sible explanation is the more basic nature of hPR3. The cal-
culated isoelectric point (pI) for mPR3 is 6.7 compared to
7.7 for hPR3. Experimental evidence points towards an even
more basic pI of 9.1 to >9.5 for hPR3 [27,28]. These ﬁndings
suggest that diﬀerences between hPR3 and mPR3 with respect
to granule release or interactions with cell surfaces can be ex-
pected under inﬂammatory conditions in vivo. Such diﬀer-
ences may be one possible explanation for our observation
that autoantibodies generated against mPR3 had signiﬁcant
pro-inﬂammatory eﬀects in wild-type mice, but did not induce
a vasculitic disease reminiscent of human ANCA-associated
vasculitis [8].
3.3. Enzymatic activities of mPR3 and mNE compared to their
human homologues
To characterize the enzymatic activities of mPR3 and mNE
compared to their human homologues, we measured kinetics
of hydrolysis of a variety of synthetic substrates (Table 1).
MeOSuc-AAPV-pNA is cleaved 10 times more eﬃciently by
mPR3 than by hPR3, and the eﬃciency of mNE and hNE
for this substrate is even 4–6 times higher than that of
mPR3, consistent with a larger S1 pocket of mPR3, mNE
and hNE compared to hPR3. MeOSuc-AIPM-pNA is most
eﬃciently cleaved by mPR3. Suc-AAA-pNA is a substrate
for both mNE and hNE. Suc-AAPL-pNA is not a good sub-
strate for any of the proteases; it is a poor substrate for
mPR3 and not cleaved by hPR3. These data indicate that sub-
strate speciﬁcity and eﬃciencies of substrate hydrolysis of
mNE are very similar to hNE, thus supporting the validity
of conclusions drawn from NE-deﬁcient mice [12,14,15,29].
In contrast, mPR3 diﬀers more substantially from hPR3. As
mPR3 seems to display some more ‘‘elastase-like’’ properties,
the distinction of mPR3 eﬀects from mNE eﬀects in murine
models seems important. Our ﬁnding that MeOSuc-AIPM-
pNA is a much better substrate for mPR3 than for mNE
may help in this respect. However, more clearly discriminating
substrates such as recently developed for hPR3 and hNE [30]
remain to be identiﬁed or developed.
Oxidized insulin B chain is characterized as a large peptide
substrate for elastases and PR3 [2,31]. Representative chro-
matograms of digests of oxidized insulin B chain are shown
in Fig. 3. Using similar substrate and enzyme concentrationsthroughout, chromatograms were compared at time points
ranging from 6 min to 20 h. Peptides were identiﬁed by amino
acid analysis and quantiﬁed by peak height. Fig. 3C and D
summarize these HPLC analyses over time for human and
murine PR3 and NE.
Both hPR3 and mPR3 cleaved rapidly at Leu17-Val18, and
the resulting carboxy-terminal peptide was slowly digested at
Val18-Cys19, yielding a stable peptide Cys19-Ala30. The amino-
terminal peptide (Phe1-Leu17) was cleaved by both enzymes at
Ala14-Leu15 (much more rapidly by hPR3) and at Val12-Glu13
(somewhat more quickly by mPR3).
Both hNE and mNE cleaved insulin B chain very eﬃciently
at Va118-Cys19, resulting in a stable Cys19-Ala30 peptide (which
was very slowly cleaved at Thr27-Pro28 by mNE, but not by
hNE) and the Phe1-Val18 peptide. This amino-terminal peptide
was quickly digested further at Leu15-Tyr16 (more slowly by
mNE), Ala14-Leu15, and Val12-Glu13. Both mNE and hNE
cleaved very slowly at Ser9-His10.
The insulin B chain cleavage results indicate that all four iso-
zymes have unique enzyme characteristics that are more com-
plex than predictable on the basis of S1 selectivity. Other
factors may contribute substantially to the preferred binding
of substrates (or inhibitors) to the enzymes. These may include
the unpredictable role of van der Waals interactions between
substrate and enzyme [32], or interactions between substrate
and diﬀering structures on the prime side of the substrate
pocket [30,33]. Consequently, screens of the substrate space
using positional scanning-synthetic combinatorial libraries ap-
pear necessary to identify optimal speciﬁc substrates (and
inhibitors) for each of the four homologue neutrophil serine
proteases [34].
In vitro experiments have identiﬁed a variety of matrix pro-
teins, cytokines and clotting factors as potential substrates for
human NE or PR3. Yet, little is known about which of these
molecular substrates are really physiologically relevant sub-
strates for PR3 and NE in vivo. Furthermore, they may be dif-
ferent in diﬀerent species. Therefore, we chose bovine
ﬁbrinogen as a potentially ‘‘physiologic’’ large molecular sub-
strate for additional comparative studies of enzymatic activity.
First, ﬁbrinogen has been described as a relevant substrate for
NE, and second, ﬁbrinogen is highly conserved across species.
Again, as shown in Fig. 4, mPR3 behaves diﬀerently from
hPR3, and more like hNE.
3.4. Inhibition of mPR3 and mNE compared to their human
homologues
To identify common and discriminating inhibitors, we deter-
mined the molar equivalents of inhibitors required to reduce
the enzymatic activity (IC50-values) of the four proteases
(Table 2). Inhibitor studies comparing the IC50-values of the
diﬀerent hPR3 and mPR3 variants (puriﬁed native PMN-
PR3, cathepsin C-activated recombinant hPR3-cmyc and
mPR3-cmyc from 293 cells) showed the same species-speciﬁc
relationships as the ones shown in Table 2. As expected,
a1-antitrypsin inhibited all of the serine protease homologues
well. Perhaps in part because of its small P1 residue (Ala), ela-
ﬁn also inhibited all of the enzymes well.
As reported [35], SLPI inhibited hNE and mNE well. It
did not inhibit hPR3 and mPR3. This observation indicates
that SLPI may be a useful tool to distinguish between
mNE and mPR3 activity in biological specimens obtained
from mice.
Table 2
Molar equivalents of inhibitor required to reduce the enzymatic
activity of human and murine PR3 and NE by ﬁfty percent
Inhibitor Human
PR3b
Murine
PR3c
Murine
NEd
Human
NEe
Val15-aprotinin LI
a 447 ± 153 142 ± 101 0.81 ± 0.37
SLPI LIa LIa 0.61 ± 0.3f 0.60 ± 0.07f
Eglin C 117 ± 72 3.3 ± 1.1 6.0 ± 3.0 0.57 ± 0.13
a-1 Antitrypsin 0.98 ± 0.29 0.74 ± 0.17 0.43 ± 0.03 1.1 ± 0.2
Elaﬁn 1.9 ± 0.1f 0.99 ± 0.02 1.0 ± 0.3f 1.4 ± 0.3
aLimited inhibition; >75% of activity remained in the presence of the
highest concentration of inhibitor.
bData shown for human PR3 were obtained with rhPR3-salt puriﬁed
from HMC-1/hPR3 cells.
cData shown for murine PR3 were obtained with rmPR3 puriﬁed from
HMC-1/mPR3 cells.
dData shown for or murine NE were obtained with rmNE-cmyc
puriﬁed from 293/mNE-cmyc cells.
eData shown for human NE were obtained with puriﬁed PMN-HNE.
fTwo determinations.
O. Wiesner et al. / FEBS Letters 579 (2005) 5305–5312 5311Eglin C, which like SLPI has a Leu at P1, was a potent
inhibitor of hNE, a signiﬁcant inhibitor of mNE and mPR3,
a poor inhibitor of hPR3. An even more striking species diﬀer-
ence between hNE and mNE was observed with the custom-
designed hNE inhibitor, Val15-aprotinin. This observation
further supports the notion that factors beyond P1–S1 interac-
tions substantially inﬂuence the interactions between enzymes
and substrates as well as inhibitors [30,32,33]. Consequently,
custom-designed inhibitors of human neutrophil serine prote-
ases need to be evaluated against their species-speciﬁc homo-
logues before conclusions about biological or therapeutic
eﬀects of such inhibitors can be extrapolated from murine
models. Our recombinant expression systems serve as a con-
venient source for puriﬁed murine neutrophil serine proteases
required for such experiments.
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